Through 2022, growth in the neuropathic pain drug market will be constrained by generics
The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents - Eli Lilly/Shionogi’s Cymbalta/Xeristar (duloxetine), Endo/Grunenthal’s Lidoderm/Versatis (lidocaine patch 5%) and Pfizer’s Lyrica (pregabalin) - combined with a lack of transformative emerging therapies forecasted to launch specifically for NP, will contribute to a slight market decline during the 2012-2022 study period.
Nevertheless, according to a report from health care advisory firm Decision Resources, the launch of several high priced, branded agents that will experience uptake in niche populations within the NP market will help to counterbalance some of the sales lost to generic erosion. Consequently, in the USA, France, Germany, Italy, Spain, the UK and Japan, combined NP market sales will decrease from $6.3 billion in 2012 to less than $6 billion in 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze